Importance Treatment of locally advanced non–small cell lung cancer (NSCLC) remains
challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with …

Purpose: Preclinical findings suggest that adding targeted therapies to combination
radiation-chemotherapy can enhance treatment efficacy; however, this approach may …

Objectives: Preclinical observations that selective cyclooxygenase-2 inhibitors enhance in
vitro cell radiosensitivity and in vivo tumor radioresponse led to clinical trials testing …

Abstract Purpose: Cyclooxygenase-2 (COX-2) plays important roles in the modulation of
apoptosis, angiogenesis, immune response, and tumor invasion. Elevated COX-2 …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …

In several pre-clinical models, cyclooxygenase (COX) inhibitors increase radio-sensitivity of
tumours, whilst not affecting normal tissues. A randomised phase II trial comparing …

Background Treatment of patients who have locally advanced non–small-cell lung cancer
and compromised performance status or weight loss (WL) is challenging. This study was …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …

Overexpression of cyclooxygenase-2 (COX-2) is frequently presentin lung cancer and may
play a significant role in carcinogenesis, invasion, and metastasis. It has been associated …

Title Phase II study of celecoxib with docetaxel chemoradiotherapy (CRT) followed by
consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in …